Myelodysplastic Syndromes
September 2021 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Myelodysplastic Syndromes abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Myelodysplastic Syndromes. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Myelodysplastic Syndromes. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Myelodysplastic Syndromes every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.
Authors:Kadia TM, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y, Dinardo CD, Daver N, Jain N, Pemmaraju N, Short N, Wang SA, Tidwell RSS, Islam R, Konopleva M, Garcia-Manero G, Ravandi F, Kantarjian HM
Institution:Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: tkadia@mdanderson.org. Houston, TX, USA. TX, USA. TX, USA. TX, USA. TX, USA. TX, USA. TX, USA. TX, USA. TX, USA. TX, USA. Houston, TX, USA. Houston, TX, USA. TX, USA. TX, USA. TX, USA. TX, USA. TX, USA.
Journal:Lancet Haematol. 2021 Aug;8(8):e552-e561. doi: 10.1016/S2352-3026(21)00192-7.

2:Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
Authors:Wei Y, Xiong X, Li X, Lu W, He X, Jin X, Sun R, Lyu H, Yuan T, Sun T, Zhao M
Institution:The First Central Clinical College of Tianjin Medical University, Tianjin, China. Tianjin, China.
Journal:Cancer Sci. 2021 Sep;112(9):3636-3644. doi: 10.1111/cas.15048. Epub 2021 Jul 21.

3:Current challenges and unmet medical needs in myelodysplastic syndromes.
Authors:Platzbecker U, Kubasch AS, Homer-Bouthiette C, Prebet T
Institution:Department of Hematology, Cellular Therapy and Hemostaseology, Leipzig University Hospital, Leipzig, Germany. Uwe.Platzbecker@medizin.uni-leipzig.de. Uwe.Platzbecker@medizin.uni-leipzig.de. Uwe.Platzbecker@medizin.uni-leipzig.de. Hospital, Leipzig, Germany.
Journal:Leukemia. 2021 Aug;35(8):2182-2198. doi: 10.1038/s41375-021-01265-7. Epub 2021 May 28.

4:Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies.
Authors:Stomper J, Rotondo JC, Greve G, Lübbert M
Institution:Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. Medicine, University of Freiburg, Freiburg, Germany. Medicine, University of Freiburg, Freiburg, Germany. Medicine, University of Freiburg, Freiburg, Germany. michael.luebbert@uniklinik-freiburg.de. michael.luebbert@uniklinik-freiburg.de.
Journal:Leukemia. 2021 Jul;35(7):1873-1889. doi: 10.1038/s41375-021-01218-0. Epub 2021 May 6.

5:Stanozolol for the treatment of anemic lower-risk myelodysplastic syndromes without del(5q) after failure of epoetin alfa: findings from a retrospective study.
Authors:Qu WY, Zhao L, Tan XC, Zhao YH
Institution:Department of Hematology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, 528 Zhangheng Road, Shanghai, 200120, China.
Journal:Ann Hematol. 2021 Jun;100(6):1451-1457. doi: 10.1007/s00277-021-04508-w. Epub 2021 Apr 10.

6:Do histone deacytelase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes?
Authors:Badar T, Atallah E
Institution:Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL, USA. of Wisconsin, USA.
Journal:Expert Opin Investig Drugs. 2021 Jun;30(6):665-673. doi: 10.1080/13543784.2021.1915986. Epub 2021 Apr 19.

7:High-dose regimens of hypomethylating agents promote transfusion independence in IPSS lower-risk myelodysplastic syndromes: a meta-analysis of prospective studies.
Authors:Wan Z, Han B
Institution:Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, China. Medical Science, China.
Journal:Aging (Albany NY). 2021 Mar 26;13(8):11120-11134. doi: 10.18632/aging.202767. Epub 2021 Mar 26.

8:Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial.
Authors:Scott BL, Pasquini MC, Fei M, Fraser R, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick E, Fernandez HF, Soiffer RJ, Alyea E, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Hourigan CS, Gui G, Mendizabal A, Horowitz MM, Deeg HJ, Horwitz ME
Institution:Fred Hutchinson Cancer Research Center, Seattle, Washington. Electronic address: bscott@fhcrc.org.
Journal:Transplant Cell Ther. 2021 Jun;27(6):483.e1-483.e6. doi: 10.1016/j.jtct.2021.02.031. Epub 2021 Feb 26.

9:Decitabine combined with low dose idarubicin and cytarabine (D-IA) followed by allo-HSCT improves acute myeloid leukemia and higher-risk myelodysplastic syndrome patient outcomes: results from a retrospective study.
Authors:Xu W, Ye L, Mei C, Zhou XP, Ren Y, Ma L, Ye X, Lu C, Jin J, Tong HY
Institution:Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China. Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China. Hangzhou, Zhejiang, PR China. of Medicine, Hangzhou, Zhejiang Province, PR China. Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China. Hangzhou, Zhejiang, PR China. of Medicine, Hangzhou, Zhejiang Province, PR China. Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China. Hangzhou, Zhejiang, PR China. of Medicine, Hangzhou, Zhejiang Province, PR China. Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China. Hangzhou, Zhejiang, PR China. of Medicine, Hangzhou, Zhejiang Province, PR China. Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China. Hangzhou, Zhejiang, PR China. of Medicine, Hangzhou, Zhejiang Province, PR China. Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China. Hangzhou, Zhejiang, PR China. of Medicine, Hangzhou, Zhejiang Province, PR China. Hangzhou, Zhejiang, PR China. Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China. of Medicine, Hangzhou, Zhejiang Province, PR China. Hangzhou, Zhejiang, PR China. of Medicine, Hangzhou, Zhejiang Province, PR China. Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China. Hangzhou, Zhejiang, PR China.
Journal:Leuk Lymphoma. 2021 Aug;62(8):1920-1929. doi: 10.1080/10428194.2021.1891230. Epub 2021 Mar 7.

10:Stanozolol improves the progression-free survival of patients with high-risk myelodysplastic syndrome after decitabine treatment.
Authors:Liu Y, Yang C, Xue H, Ye F, Sun W, Wang J, Qi W, Niu H, Hua L, Wang H, Han B, Shao Z
Institution:Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, 300052, China. shaozonghong@tmu.edu.cn.
Journal:Int J Hematol. 2021 Jun;113(6):807-814. doi: 10.1007/s12185-021-03115-9. Epub 2021 Mar 1.

11:Factors affecting response to 5-azacytidine and prognosis of myelodysplastic syndrome. Is long-term survival a realistic goal?
Authors:Diamantopoulos PT, Viniou NA
Institution:First Department of Internal Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: pandiamantopoulos@gmail.com.
Journal:Leuk Res. 2021 Apr;103:106543. doi: 10.1016/j.leukres.2021.106543. Epub 2021 Feb 20.

12:Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis.
Authors:Stein EM, Bonifacio G, Latremouille-Viau D, Shi S, Guerin A, Wu EQ, Sadek I, Cao X
Institution:Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Health Economics and Outcomes Research, US Oncology, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Journal:Leuk Lymphoma. 2021 Jun;62(6):1411-1421. doi: 10.1080/10428194.2020.1869959. Epub 2021 Jan 11.

13:Current and emerging strategies for management of myelodysplastic syndromes.
Authors:Saygin C, Carraway HE
Institution:Section of Hematology/Oncology, University of Chicago, Chicago, IL 60637, USA. USA. Electronic address: carrawh@ccf.org.
Journal:Blood Rev. 2021 Jul;48:100791. doi: 10.1016/j.blre.2020.100791. Epub 2020 Dec 27.

14:Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?
Authors:Abel GA, Kim HT, Hantel A, Steensma DP, Stone R, Habib A, Ho VT, Wadleigh M, El-Jawahri A, Alyea EP, DeAngelo DJ, Koreth J, Antin JH, Soiffer RJ, Cutler C
Institution:Dana-Farber Cancer Institute, Boston, MA, USA. gregory_abel@dfci.harvard.edu.
Journal:Leukemia. 2021 Apr;35(4):1166-1175. doi: 10.1038/s41375-020-01092-2. Epub 2020 Nov 17.

15:Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Authors:Schuler E, Wagner-Drouet EM, Ajib S, Bug G, Crysandt M, Dressler S, Hausmann A, Heidenreich D, Hirschbühl K, Hoepting M, Jost E, Kaivers J, Klein S, Koldehoff M, Kordelas L, Kriege O, Müller LP, Rautenberg C, Schaffrath J, Schmid C, Wolff D, Haas R, Bornhäuser M, Schroeder T, Kobbe G
Institution:Department of Hematology, Oncology and Clinical Immunology, University Hospital Dusseldorf, Medical Faculty, Heinrich Heine University, Moorenstr. 5, 40225, Dusseldorf, Germany. Esther.schuler@med.uni-duesseldorf.de.
Journal:Ann Hematol. 2021 Apr;100(4):959-968. doi: 10.1007/s00277-020-04321-x. Epub 2020 Nov 16.

16:The effect of 5-azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes.
Authors:Diamantopoulos PT, Symeonidis A, Pappa V, Kotsianidis I, Galanopoulos A, Pontikoglou C, Anagnostopoulos A, Vassilopoulos G, Zikos P, Hatzimichael E, Papaioannou M, Megalakaki A, Repousis P, Kotsopoulou M, Dimou M, Solomou E, Dryllis G, Tsokanas D, Papoutselis MK, Papageorgiou S, Kyrtshonis MC, Kourakli A, Papadaki H, Panayiotidis P, Viniou NA
Institution:Hematology Unit, First Department of Internal Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece. Hospital, National and Kapodistrian University of Athens, Athens, Greece. Greece. Athens, Greece. Chortiatis, Greece. Larissa, Greece. Thessaloniki, Greece. Kapodistrian University of Athens, Athens, Greece. National and Kapodistrian University of Athens, Athens, Greece. Athens, Greece. Greece. Hospital, National and Kapodistrian University of Athens, Athens, Greece. Kapodistrian University of Athens, Athens, Greece. Kapodistrian University of Athens, Athens, Greece. National and Kapodistrian University of Athens, Athens, Greece.
Journal:Br J Haematol. 2021 Mar;192(6):978-987. doi: 10.1111/bjh.17062. Epub 2020 Aug 30.

For a FREE PREVIEW of the Medifocus Guidebook on Myelodysplastic Syndromes click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Myelodysplastic Syndromes click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Myelodysplastic Syndromes...
at a Special 20% Discount


Medifocus Guidebook on Myelodysplastic Syndromes

Updated: July 6, 2021
217 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Myelodysplastic Syndromes is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

MS63946058

Coupon Expires: November 25, 2021



What Our Customers Are Saying...

"I purchased the MediFocus Guidebook on Myelodysplastic Syndromes to help my father understand the disease that he has. Doctors in France do not communicate very well the various treatment options neither do they tell you about the prognosis with enough clarity and confidence. We live in France and we believe there is no equivalent in Europe to the service you offer. We have read the Guidebook attentively and have learned a great deal about this condition. The wording is simple enough to be understandable even for non-native English speakers. It was money well spent!"
P.M.
Saint Ismier, France


"Your MediFocus Guidebook on Myelodysplastic Syndromes has been a valuable companion in providing wise counsel to a beleaguered soul. Many times I was comforted by knowing that I could have my questions answered correctly and completely by using your Guidebook. I wouldn't be without it for anything. Thank you again and again."
S.M.
Rockville, Maryland


"Your Medifocus Guidebook on Myelodysplastic Syndromes has been extremely valuable to me in understanding the complicated disease that afflicts me. It can be very depressing but to understand it intellectually can be very calming and heartening. Fear of the unknown is most devastating and your Guidebook provides the facts in an understandable way without 'watering-down' the science. Thank you for your outstanding publication."
N.M.
Los Angeles, California



  
Medifocus Digest Alert is published by Medifocus, Inc.
3809 Clarks Lane, Suite 100, Baltimore, MD 21215 USA
Copyright © 2021 Medifocus, Inc. All rights reserved.